Tarsus Pharmaceuticals (NASDAQ: TARS) reported that its general counsel, Bryan Wahl, sold a combined 12,440 shares of the company's common stock across three transactions executed from March 17 through March 19, 2026. The total proceeds from those sales were approximately $850,417.
The individual transactions were reported on a Form 4 filing. On March 17, Wahl sold 4,084 shares at $69.42 per share. The following day, March 18, he sold 4,125 shares at $68.71 per share. The sequence concluded on March 19 with a sale of 4,231 shares at $67.00 per share. After the transactions, Wahl is recorded as directly owning 63,959 shares of Tarsus Pharmaceuticals.
The filings specify that the shares sold were used to satisfy tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs). The sales were undertaken in accordance with Tarsus Pharmaceuticals’ election to require that tax-withholding obligations be funded through a "sell to cover" mechanism. The company and filing indicate these were not discretionary sales by Wahl.
Market context supplied in the filing notes that Tarsus' stock was trading at $66.75 at the time of the report. Over the trailing 12 months, shares are up about 35%, although they have declined roughly 18% year to date.
Independent analysis cited in the filing characterizes Tarsus as appearing undervalued at current levels and highlights that the company carries more cash than debt on its balance sheet. That analysis assigns a Financial Health Score of "GOOD" and references a comprehensive Pro Research Report for further detail.
In related corporate reporting, Tarsus Pharmaceuticals disclosed strong financial performance for the fourth quarter of 2025, with net product sales of $151.7 million for the quarter and $451.4 million for the full year. The company attributed the substantial increase in revenue and profitability to the performance of its lead product, XDEMVY. Those results were described as marking a pivotal period of growth for the company.
Despite the quarterly strength, the stock registered a small decline in aftermarket trading following the results. Analysts noted the robust revenue growth, while investor response was described as nuanced.
This report is limited to the transactions and statements disclosed in the company filings and the summary of company performance referenced in the filing. It does not reflect any additional analysis beyond the facts and characterizations provided in those disclosures.